EFFECTS OF CYP2C9☆13 ALLELE ON THE PHARMACOKINETICS OF IRBESARTAN

被引：0
|
作者：
Park, J., I [1 ]
Choi, C., I [1 ]
Bae, J. W. [1 ]
Jang, C. G. [1 ]
Lee, S. Y. [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Pharm, Seoul, South Korea
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2011年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [31] Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy
    Muhammad, Sumaira Deen
    Khan, Hazar
    Hussain, Mushtaq
    Zeb, Tehseen Fatima
    Kumar, Darshan
    Rahi, Rahimullah
    Asif, Mahayrookh
    Balooch, Akhter Ali
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 33 (04) : 1771 - 1777
  • [32] CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians
    Vianna-Jorge, R
    Perini, JA
    Rondinelli, E
    Suarez-Kurtz, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (01) : 18 - 26
  • [33] Identification of a novel variant CYP2C9 allele in Chinese
    Si, DY
    Guo, YJ
    Zhang, YF
    Yang, L
    Zhou, H
    Zhong, DF
    PHARMACOGENETICS, 2004, 14 (07): : 465 - 469
  • [34] Effect of the CYP2C9*3 allele on lornoxicam metabolism
    Liu, YL
    Zhang, W
    Tan, ZR
    Ouyang, DS
    Luo, CH
    Liu, ZQ
    Qiu, Y
    Chen, Y
    He, YJ
    Zhou, G
    Zhou, HH
    CLINICA CHIMICA ACTA, 2006, 364 (1-2) : 287 - 291
  • [35] Allele and genotype frequency of CYP2C9 in Tamilnadu population
    C. Adithan
    N. Gerard
    S. Vasu
    R. Balakrishnan
    C. H. Shashindran
    R. Krishnamoorthy
    European Journal of Clinical Pharmacology, 2003, 59 : 707 - 709
  • [36] Characterization of the novel defective CYP2C9*24 allele
    Herman, Darja
    Dolzan, Vita
    Ingelman-Sundberg, Magnus
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (06) : 831 - 834
  • [37] Allele and genotype frequencies of CYP2C9 in a Korean population
    Bae, JW
    Kim, HK
    Kim, JH
    Yang, SI
    Kim, MJ
    Jang, CG
    Park, YS
    Lee, SY
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 418 - 422
  • [38] Allele frequency of CYP2C9 gene polymorphisms in Iran
    Peyvandi, F
    Spreafico, M
    Karimi, M
    Zeinali, S
    Mannucci, PM
    THROMBOSIS AND HAEMOSTASIS, 2002, 88 (05) : 874 - 875
  • [39] The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
    Meadowcroft, AM
    Williamson, KM
    Patterson, JH
    Hinderliter, AL
    Pieper, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (04): : 418 - 424
  • [40] Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan
    Bae, Jung-Woo
    Han, Ho-Kyun
    Lee, Hwan-Joo
    Jung, Dong -Won
    Kim, Nam-Tae
    Lee, Jin-Hee
    Jang, Choon-Gon
    Choi, Sun-Ok
    Kim, Ok-Hee
    Lee, Seok-Yong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 230 - 231
12345